# Italian healthcare resource consumptions and direct costs of adults with atopic dermatitis before and after dupilumab treatment

First published: 04/10/2024 Last updated: 04/10/2024





## Administrative details

**Study description** 

EU PAS number	
EUPAS1000000328	
Study ID	
1000000328	
DADWIN ELL® study	
DARWIN EU® study	
No	
Study countries	
Italy	

Background: Atopic dermatitis (AD) is a heterogeneous disease, associated with comorbidities, and high healthcare consumptions and costs. This study assessed the burden before and after treatment with dupilumab in adults with severe AD from 2018 to 2020, from the perspective of the Italian National Health Service (SSN).

Methods: From Fondazione Ricerca e Salute's administrative healthcare database (~5 million inhabitants/year), adults treated with dupilumab from 09/01/2018 to 31/12/2020 (index date) and a five-year lookback were identified. Age, sex and comorbidities at baseline, concomitant drugs, overnight hospitalizations, outpatient specialist services and direct costs charged to the SSN one year before/after index date were assessed.

Results: Of 337 adults treated with dupilumab (5.8x100,000 adult inhabitants/2019; 8.0x100,000/2020; 55% males; mean age 43±19), 68% (228/337) had ≥12-month follow-up available. Asthma was a common comorbidity (23% patients). Rates of patients treated with nearly all concomitant AD-related therapies reduced from 12 months before to 12 months after dupilumab treatment: antibacterials (from 59% to 50%), systemic corticosteroids (55% to 29%), antihistamines (54% to 38%) and cyclosporine (52% to 7%). A similar trend was observed among patients with asthma as comorbidity. Within 12 months before/after dupilumab, patients hospitalized halved from 14% to 7%, and patients receiving outpatient specialist care reduced from 72% to 65%. Annual mean direct total costs per patient treated with dupilumab charged to the SSN, net of dupilumab cost, were €1384 and €773, before and after dupilumab dispensation, respectively.

Conclusions: Before dupilumab, observed patients had higher healthcare resource consumptions and direct SSN costs than after dupilumab.

#### Study status

Finalised

## Research institutions and networks

## Institutions

Fondazione ReS (Ricerca e Salute), CINECA partner	
Italy	
First published: 05/07/2017	
<b>Last updated:</b> 01/10/2025	
Institution Not-for-profit ENCePP partner	

## Contact details

## **Study institution contact**

Silvia Calabria calabria@fondazioneres.it

Study contact

calabria@fondazioneres.it

## **Primary lead investigator**

Letizia Dondi

Primary lead investigator

# Study timelines

Date when funding contract was signed

Actual: 30/06/2022

Study start date

Actual: 30/07/2022

#### **Date of final study report**

Actual: 30/12/2022

# Sources of funding

• Pharmaceutical company and other private sector

# More details on funding

This article is funded by Sanofi.

# Regulatory

Was the study required by a regulatory body?

No

Is the study required by a Risk Management Plan (RMP)?

Not applicable

# Methodological aspects

Study type

Study type list

#### **Study topic:**

Disease /health condition

Human medicinal product

#### Study type:

Non-interventional study

#### Scope of the study:

Drug utilisation

Healthcare resource utilisation

#### **Data collection methods:**

Secondary use of data

#### Study design:

Adults treated with dupilumab from 09/01/2018 to 31/12/2020 (index date) were identified. Age, sex and comorbidities during a five-year lookback period, concomitant drugs, overnight hospitalization, outpatient specialist services and direct costs charged to the SSN one year before/after index date

#### Main study objective:

This study assessed the burden before and after treatment with dupilumab in adults with severe AD from 2018 to 2020, from the perspective of the Italian National Health Service (SSN).

## Study Design

#### Non-interventional study design

Cohort

# Study drug and medical condition

#### **Medicinal product name**

**DUPIXENT** 

## Study drug International non-proprietary name (INN) or common name

**DUPILUMAB** 

#### **Anatomical Therapeutic Chemical (ATC) code**

(D11AH05) dupilumab dupilumab

#### Medical condition to be studied

Dermatitis atopic

#### Additional medical condition(s)

Severe atopic dermatitis

# Population studied

#### Short description of the study population

Adults with at least one supply of dupilumab (ATC code D11AH05) from 1st September 2018 to 1st December 2020, with a five-year lookback period and until 31st December 2020. Given that, in Italy, the reimbursement of dupilumab for adult patients was granted to severe AD (eligibility criteria: EASI score ≥24 who have failed or are inadvisable for the treatment with cyclosporine) until the beginning of December 2020, the dispensation of dupilumab during the accrual period, from 1st September 2018 to 1st December 2020, was used as the specific inclusion criterion to identify patients with AD (namely, the only indication reimbursed at that time).

#### Age groups

- Adult and elderly population (≥18 years)
  - Adults (18 to < 65 years)</li>
    - Adults (18 to < 46 years)
    - Adults (46 to < 65 years)
  - Elderly (≥ 65 years)
    - Adults (65 to < 75 years)
    - Adults (75 to < 85 years)
    - Adults (85 years and over)

#### **Estimated number of subjects**

337

# Study design details

#### **Setting**

Inpatient and local outpatient

#### **Summary results**

Of 337 adults treated with dupilumab (5.8×100,000 adult inhabitants/2019; 8.0×100,000/2020; 55% males; mean age 43±19), 68% (228/337) had ≥12-month follow-up available. Asthma was a common comorbidity (23% patients). Rates of patients treated with nearly all concomitant AD-related therapies reduced from 12 months before to 12 months after dupilumab treatment: antibacterials (from 59% to 50%), systemic corticosteroids (55% to 29%), antihistamines (54% to 38%) and cyclosporine (52% to 7%). A similar trend was observed among patients with asthma as comorbidity. Within 12 months before/after dupilumab, patients hospitalized halved from 14% to 7%, and patients receiving outpatient specialist care reduced from 72% to 65%. Annual

mean direct total costs per patient treated with dupilumab charged to the SSN, net of dupilumab cost, were €1384 and €773, before and after dupilumab dispensation, respectively.

## **Documents**

#### **Study publications**

Italian healthcare resource consumptions and direct costs of adults with atopic...

# Data management

## **ENCePP Seal**

The use of the ENCePP Seal has been discontinued since February 2025.

The ENCePP Seal fields are retained in the display mode for transparency but are no longer maintained.

## Data sources

#### Data source(s)

Database of Fondazione ReS

#### **Data sources (types)**

Administrative healthcare records (e.g., claims)

# Use of a Common Data Model (CDM)

#### **CDM** mapping

No

# Data quality specifications

#### **Check conformance**

Yes

## **Check completeness**

Yes

## **Check stability**

Yes

## **Check logical consistency**

Yes

## Data characterisation

#### **Data characterisation conducted**

Yes